CVRx (NASDAQ: CVRX), developer of the implantable Barostim neuromodulation device for treating heart failure symptoms, had first-quarter sales that missed the Wall Street consensus by more than $2 million. That’s according to the preliminary Q1 results that the Minneapolis-based company released after market close yesterday. By the afternoon today, CVRX shares were down more than […]
cvrx
CVRx stock dips on Q4 EPS miss
CVRx (Nasdaq:CVRX) shares took a hit today on fourth-quarter results that fell short of earnings per share expectations. Shares of CVRX fell 10% to $14.63 apiece in mid-morning trading today. The Minneapolis-based maker of neuromodulation devices for treating heart failure reported losses of $10.65 million. That equals 43¢ per share on sales of $15.34 million […]
CVRx earns Medicare win for Barostim procedure
CVRx (Nasdaq:CVRX) announced today that the Centers for Medicare and Medicaid Services (CMS) assigned a new payment classification for its Barostim device. Barostim delivers electrical pulses to baroreceptors in the wall of the carotid artery. The pulses activate the body’s baroreflex, triggering an autonomic response to the heart. CVRx designed the therapy to restore balance […]
CVRx has more positive Barostim data
CVRx (Nasdaq:CVRX) today announced new data supporting its Barostim technology for treating heart failure. Barostim delivers electrical pulses to baroreceptors in the wall of the carotid artery. The pulses activate the body’s baroreflex, triggering an autonomic response to the heart. CVRx designed the therapy to restore balance to the autonomic nervous system, reducing the symptoms […]
CVRx adds two new faces to its board as long-serving member departs
CVRx (Nasdaq:CVRX) announced today that it appointed Kevin Ballinger and Mitch Hill to its board of directors, effective immediately. “We are thrilled to welcome Kevin and Mitch to our Board of Directors,” said Kevin Hykes, President and CEO of CVRx. “Their extensive experience in the medical device industry, coupled with their strong track records driving […]
CVRx earns Medicare win for Barostim procedure
CVRx (Nasdaq:CVRX) announced today that the Centers for Medicare and Medicaid Services (CMS) reassigned its Barostim implant procedure. CMS reassigned Barostim for the inpatient setting as part of the Fiscal Year (FY) 2025 Medicare Hospital Inpatient Prospective Payment System (IPPS) final rule. In FY 2024, CMS assigned Barostim to MS-DRGs 252, 253, 254. That had […]
CVRx stock is down on mixed Q2 results, unchanged guidance
CVRx (NASDAQ: CVRX) — developer of the implantable Barostim neuromodulation device for treating heart failure symptoms — reported mixed second-quarter results and unchanged guidance. The earnings news, released after yesterday’s market close, sent the Minneapolis-based company’s shares down more than 15% to $7.85 apiece by afternoon trading today. MassDevice’s MedTech 100 Index, which includes stocks […]
CVRx bolsters its executive ranks with hires from Abbott, Medtronic
CVRx (NASDAQ: CVRX) is hiring talent from Abbott and Medtronic to bolster the adoption of its Barostim device for treating heart failure symptoms. In an email to CVRx employees shared with MassDevice, CEO Kevin Hykes repeated that the Minneapolis-based company is refining its commercial strategy. “This means increasing our capabilities and focusing on broadening therapy […]
CVRx has more data supporting long-term benefits of Barostim
CVRx (Nasdaq:CVRX) announced the publication of post-market data highlighting long-term, sustained benefits with its Barostim device. Minneapolis-based CVRx published results from the BeAT-HF trial in the European Journal of Heart Failure. Data supported Barostim treatment in heart failure patients with reduced ejection fraction. Barostim delivers electrical pulses to baroreceptors in the wall of the carotid […]
Augmedics CEO is taking over corner office at CVRx
CVRx (Nasdaq:CVRX) announced today that it appointed Kevin Hykes as its new president and CEO, effective Feb. 12. Hykes already has familiarity with the Minneapolis-based neurostimulation technology developer, having joined its board in December 2022. He will continue to serve on the board, with CEO Nadim Yared set to retire from the company and resign […]
CVRx stock dips despite Street-beating Q4
CVRx (Nasdaq:CVRX) shares took a hit today despite fourth-quarter results that beat the consensus forecast. Shares of CVRx fell 5.2% at $27.69 apiece in mid-afternoon trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 0.2%. The Minneapolis-based neuromodulation technology developer posted losses of $9.2 million. […]
